April 19, 2024
Market Now
Celltrion signs W60.4b contact with affiliate
[DISCLOSURE] Celltrion (068270) announced on April 20 that it has signed a sales contract worth 60.35 billion won (US$52.80 million) for its biosimilar Remsima with its affiliate Celltrion Healthcare.
This amounts to 9 percent of its 2016 revenue and the contract is valid until April 30.
By Hwang You-mee (theinvestor@heraldcorp.com)
This amounts to 9 percent of its 2016 revenue and the contract is valid until April 30.
By Hwang You-mee (theinvestor@heraldcorp.com)
